ArticleDiabetes2010
Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism.
Article in Diabetes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Trial
- Association ofBioscience reports · 2019Trial
- Role of interleukin-16 in human diseases: a novel potential therapeutic target.Frontiers in immunology · 2025Review
- Article
- Interleukin-16 is increased in obesity and alters adipogenesis and inflammationFrontiers in endocrinology · 2024Article
- [Expression and clinical significance of interleukin-16 in patients with primary biliary cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Association of IL-16 rs11556218 T/G polymorphism with the risk of developing type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2021Article
- Subcutaneous transplantation of engineered islet/adipose-derived mesenchymal stem cell sheets in diabetic pigs with total pancreatectomy.Regenerative therapy · 2021Article
- A Novel Resolution of Diabetes: C-C Chemokine Motif Ligand 4 Is a Common Target in Different Types of Diabetes by Protecting Pancreatic Islet Cell and Modulating Inflammation.Frontiers in immunology · 2021Article
- Human Islet Response to Selected Type 1 Diabetes-Associated Bacteria: A Transcriptome-Based Study.Frontiers in immunology · 2019Article
- High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.Frontiers in immunology · 2019Article
- Associations of Circulating Protein Levels With Lipid Fractions in the General Population.Arteriosclerosis, thrombosis, and vascular biology · 2018Article
- A genome-wide association study identifies six novel risk loci for primary biliary cholangitis.Nature communications · 2017Article
- Body mass index, inflammatory biomarkers and neurocognitive impairment in HIV-infected persons.Psychology, health & medicine · 2017Article
- Neutrophil-Derived Interleukin 16 in Premetastatic Lungs Promotes Breast Tumor Cell Seeding.Cancer growth and metastasis · 2017Article
- Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Emerging role of chemokine CC motif ligand 4 related mechanisms in diabetes mellitus and cardiovascular disease: friends or foes?Cardiovascular diabetology · 2016Review
- Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD.International journal of chronic obstructive pulmonary disease · 2016Article
- Large-Scale Discovery and Validation Studies Demonstrate Significant Reductions in Circulating Levels of IL8, IL-1Ra, MCP-1, and MIP-1β in Patients With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2015Article
- Secretion of IL-16 through TNFR1 and calpain-caspase signaling contributes to MRSA pneumonia.Mucosal immunology · 2014Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe progressive infiltration of pancreatic islets by lymphocytes is mandatory for development of autoimmune type 1 diabetes. This inflammatory process is mediated by several mediators that are potential therapeutic targets to arrest development of type 1 diabetes. In this study, we investigate the role of one of these mediators, interleukin-16 (IL-16), in the pathogenesis of type 1 diabetes in NOD mice. RESEARCH DESIGN AND
methodsAt different stages of progression of type 1 diabetes, we characterized IL-16 in islets using GEArray technology and immunoblot analysis and also quantitated IL-16 activity in cell migration assays. IL-16 expression was localized in islets by immunofluorescence and confocal imaging. In vivo neutralization studies were performed to assess the role of IL-16 in the pathogenesis of type 1 diabetes.
resultsThe increased expression of IL-16 in islets correlated with the development of invasive insulitis. IL-16 immunoreactivity was found in islet infiltrating T-cells, B-cells, NK-cells, and dendritic cells, and within an insulitic lesion, IL-16 was derived from infiltrating cells. CD4(+) and CD8(+) T-cells as well as B220(+) B-cells were identified as sources of secreted IL-16. Blockade of IL-16 in vivo protected against type 1 diabetes by interfering with recruitment of CD4(+) T-cells to the pancreas, and this protection required the activity of the chemokine CCL4.
conclusionsIL-16 production by leukocytes in islets augments the severity of insulitis during the onset of type 1 diabetes. IL-16 and CCL4 appear to function as counterregulatory proteins during disease development. Neutralization of IL-16 may represent a novel therapy for the prevention of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.